Publications in collaboration with researchers from University of Turin (61)

2022

  1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414

  2. Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322

    Annals of oncology : official journal of the European Society for Medical Oncology

  3. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

  4. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

    American Journal of Hematology, Vol. 97, Núm. 4, pp. 481-490

  5. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Leukemia, Vol. 36, Núm. 5, pp. 1371-1376

  6. Melflufen for the treatment of multiple myeloma

    Expert Review of Clinical Pharmacology

  7. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  8. Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Current Medical Research and Opinion, Vol. 38, Núm. 10, pp. 1759-1767

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Journal of Clinical Oncology, Vol. 364